Abstract
A2B adenosine receptors have been investigated in recent years as potential target for the treatment of different pathologies. The involvement of this receptor in processes such as interleukins secretion, Ca2+ mobilization, hepatic glucose regulation, tumor vascularisation, and cardioprotection have stimulated many researchers to develop specific agonists and antagonists. For many years, the lack of potent and selective A2B ligands precluded a deep exploration of their therapeutic prospective; at present, much progress in the field of antagonists led to preclinical studies for different compounds. Less populated is the universe of A2B agonists, but really promising for the involvement in ischemic preconditioning. A summary of the most significant advancements in the synthesis of new compounds and of the principal structure activity relationships is reported. The xanthine-based A2B antagonists currently show the better profile of affinity and selectivity, as CVT-6883 (CVT-Therapeutics: Ki(A2B)=22 nM, and selectivity higher than 50-fold over other subtypes), MRE-2029-F20 (Baraldis group: Ki(A2B)=5.5 nM, selectivity > 180 fold), LAS38096 (Almirall Prodesfarma: Ki(A2B)=17 nM, selectivity > 60 fold), OSIP339391 (OSI Pharmaceuticals: Ki(A2B)=0.5 nM, selectivity > 80 fold), PSB601 (Bonn University: Ki(A2B)=3.6 nM, selectivity > 140 fold) and the deazaxanthine 32 of Carottis group (Ki(A2B)=11 nM, selectivity > 90 fold). Other recently emerging scaffolds with promising biological profiles are described. With regard to the agonists, many research groups are involved in the discovery of useful agonist radioligands, but the only example of potent and rather selective A2B agonists are compound 65, recently synthesized, and BAY-60-6583, that is under preclinical phase investigation.
Keywords: A2B, A2B antagonist, A2B agonist, A2B receptor, CVT-6883, MRE-2029-F20, LAS38096, OSIP339391, PSB601, BAY-60-6583, Asthma, inflammation, angiogenic diseases, atherosclerosis, cardioprotection, tumor
Current Topics in Medicinal Chemistry
Title: A2B Receptor Ligands: Past, Present and Future Trends
Volume: 10 Issue: 9
Author(s): G. Ortore and A. Martinelli
Affiliation:
Keywords: A2B, A2B antagonist, A2B agonist, A2B receptor, CVT-6883, MRE-2029-F20, LAS38096, OSIP339391, PSB601, BAY-60-6583, Asthma, inflammation, angiogenic diseases, atherosclerosis, cardioprotection, tumor
Abstract: A2B adenosine receptors have been investigated in recent years as potential target for the treatment of different pathologies. The involvement of this receptor in processes such as interleukins secretion, Ca2+ mobilization, hepatic glucose regulation, tumor vascularisation, and cardioprotection have stimulated many researchers to develop specific agonists and antagonists. For many years, the lack of potent and selective A2B ligands precluded a deep exploration of their therapeutic prospective; at present, much progress in the field of antagonists led to preclinical studies for different compounds. Less populated is the universe of A2B agonists, but really promising for the involvement in ischemic preconditioning. A summary of the most significant advancements in the synthesis of new compounds and of the principal structure activity relationships is reported. The xanthine-based A2B antagonists currently show the better profile of affinity and selectivity, as CVT-6883 (CVT-Therapeutics: Ki(A2B)=22 nM, and selectivity higher than 50-fold over other subtypes), MRE-2029-F20 (Baraldis group: Ki(A2B)=5.5 nM, selectivity > 180 fold), LAS38096 (Almirall Prodesfarma: Ki(A2B)=17 nM, selectivity > 60 fold), OSIP339391 (OSI Pharmaceuticals: Ki(A2B)=0.5 nM, selectivity > 80 fold), PSB601 (Bonn University: Ki(A2B)=3.6 nM, selectivity > 140 fold) and the deazaxanthine 32 of Carottis group (Ki(A2B)=11 nM, selectivity > 90 fold). Other recently emerging scaffolds with promising biological profiles are described. With regard to the agonists, many research groups are involved in the discovery of useful agonist radioligands, but the only example of potent and rather selective A2B agonists are compound 65, recently synthesized, and BAY-60-6583, that is under preclinical phase investigation.
Export Options
About this article
Cite this article as:
Ortore G. and Martinelli A., A2B Receptor Ligands: Past, Present and Future Trends, Current Topics in Medicinal Chemistry 2010; 10 (9) . https://dx.doi.org/10.2174/156802610791268747
DOI https://dx.doi.org/10.2174/156802610791268747 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Tyrosine Kinase Inhibitor as a new Therapy for Ischemic Stroke and other Neurologic Diseases: is there any Hope for a Better Outcome?
Current Neuropharmacology Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and Applications
Current Molecular Medicine Anti-Inflammatory Iridoids of Botanical Origin
Current Medicinal Chemistry Exercise-Induced Overexpression of Angiogenic Factors and Reduction of Ischemia / Reperfusion Injury in Stroke
Current Neurovascular Research Meet Our Editorial Board Member
Current Pharmaceutical Design Melatonin, A Natural Programmed Cell Death Inducer in Cancer
Current Medicinal Chemistry PI-3 Kinase-PTEN Signaling Node: An Intercept Point for the Control of Angiogenesis
Current Pharmaceutical Design Pathophysiology of the Vascular Wall and its Relevance for Cerebrovascular Disorders in Aged Rodents
Current Neurovascular Research AMP-activated Protein Kinase as a Drug Target in Chronic Kidney Disease
Current Drug Targets Role of Molecular Hydrogen in Skin Diseases and its Impact in Beauty
Current Pharmaceutical Design Gene Silencing using siRNA for Preventing Liver Ischaemia-Reperfusion Injury
Current Pharmaceutical Design Baccharis trimera Improves the Antioxidant Defense System and Inhibits iNOS and NADPH Oxidase Expression in a Rat Model of Inflammation
Current Pharmaceutical Biotechnology The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target
Current Neuropharmacology Highlighting the Protective or Degenerative Role of AMPK Activators in Dementia Experimental Models
CNS & Neurological Disorders - Drug Targets Protective Effects of Caffeic Acid and the Alzheimer's Brain: An Update
Mini-Reviews in Medicinal Chemistry A panoramic view of chronic liver diseases and natural remedies reported in Traditional Persian Medicine
Current Pharmaceutical Design Biomarkers Associated with Stroke Risk in Atrial Fibrillation
Current Medicinal Chemistry Key miRNAs in Modulating Aging and Longevity: A Focus on Signaling Pathways and Cellular Targets
Current Molecular Pharmacology Bilirubin Chemistry and Metabolism; Harmful and Protective Aspects
Current Pharmaceutical Design Cytokines and Chemokines as Regulators of Angiogenesis in Health and Disease
Current Pharmaceutical Design